UNMC to enroll up to 1,000 people for investigational vaccine study
The University of Nebraska Medical Center and Nebraska Medicine is involved in a clinical trial to test the safety and effectiveness of an investigational COVID-19 vaccine for adults. The medical center plans to enroll up to 1,000 people for the clinical trial.
For this clinical trial, the medical center is working with the COVID-19 Prevention Network (CoVPN), formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health to respond to the pandemic. Thousands of study participants have been enrolled across several large studies to test several possible SARS-CoV-2 vaccines. The investigational vaccine used for this clinical trial was developed by Novavax, Inc., a U.S. biotechnology company, which plans to enroll 30,000 adults in the U.S. and Mexico.
Press Kit Documents
- Press release (PDF)
- Press release (Word doc)
- Vaccine clinical trial webpage
- Photo of Diana Florescu, MD
Diana Florescu, MD, professor and infectious diseases specialist in the UNMC Department of Internal Medicine, is leading the Phase 3 clinical trial at UNMC.
“We are grateful and excited that UNMC was chosen as a site for this important work. Our hope is that this vaccine will prevent people from developing severe disease and decrease the chances of being hospitalized or dying."
“We encourage individuals who won’t be receiving the Pfizer or Moderna vaccines in the next three to six months to consider enrolling in the clinical trial. Participants in the Novavax vaccine clinical trial can still receive the Pfizer or Moderna vaccines when it is available to them and still remain in the trial.”
“Like everyone else, we want to beat this pandemic, To do so, we need multiple, safe and effective COVID-19 vaccines. We also want to involve the most vulnerable communities: minorities, people over the age of 65, and those with other health conditions.”
“For more information, go to unmc.edu forward slash COVID vaccine trial.”